98%
921
2 minutes
20
After myocardial infarction (MI), the affected area of the myocardium falls into a state of ischemia and hypoxia, and subsequently, cardiomyocytes undergo a series of pathological changes and eventually transform into scar tissue. Therefore, restoring blood perfusion and reducing reactive oxygen species (ROS) are essential to promote the repair process of damaged myocardium. Here, the MMP12 (YWDAW) peptide which has a good antioxidant effect in deep-sea fish muscle, and the KRX (MRPYDANKR) peptide which shows a pro-angiogenesis effect from mammalian endothelial genes, were utilized collaboratively and loaded into an injectable GelMA hydrogel to achieve minimally invasive implantation and long-term retention at the MI site. The incorporation of bioactive peptides builds a stable and efficient system, which in addition to effectively removing ROS and promoting angiogenesis, avoids cell apoptosis and inflammation in the long run, and effectively inhibits the process of myocardial fibrosis. Both in vivo and in vitro experiments have shown that the combination of two short peptides with anti-oxidation and angiogenesis therapy can eventually achieve rapid repair of damaged myocardial tissue. This study fully demonstrated that natural functional peptides have great potential in promoting the repair and regeneration of infarcted hearts. STATEMENT OF SIGNIFICANCE: We have successfully synthesized antioxidant and pro-angiogenic peptides, which were subsequently incorporated into an injectable hydrogel matrix. This bioactive hydrogel system demonstrates dual therapeutic functions, effectively scavenging ROS while promoting angiogenesis, thereby facilitating cardiac tissue repair. Notably, the chemical synthesis approach employed in peptide production establishes a robust foundation for scalable manufacturing and broad biomedical applications, particularly in cardiovascular therapeutics.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.actbio.2025.03.035 | DOI Listing |
JACC Heart Fail
September 2025
Université de Lorraine, Inserm, Centre d'Investigations Cliniques Plurithématique 1433, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.
Eur J Cardiothorac Surg
September 2025
Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
Objectives: The no-touch (NT) technique for saphenous vein (SV) harvesting in coronary artery bypass surgery preserves perivascular tissue and has been proposed to improve vein graft patency compared to conventional (CON) harvesting. However, recent large randomized clinical trials (RCTs) have reported conflicting results. We performed a meta-analysis of all available RCTs comparing graft patency and clinical outcomes between NT-SV and CON-SV harvesting techniques.
View Article and Find Full Text PDFEur Heart J Qual Care Clin Outcomes
September 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Background And Aims: Additional epidemiologic evidence is warranted regarding the appropriate timing of statin initiation for incidentally found dyslipidemia in general health check-ups. This study examined the association between the statin initiation timing and the risk of myocardial infarction (MI) in individuals with incidentally detected high low-density-lipoprotein cholesterol (LDL-C).
Methods: Participants aged 20 years or older who underwent annual health checkups from 2009 to 2012 were included.
J Invasive Cardiol
September 2025
Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota. Email:
Objectives: Additional studies are needed on the follow-up outcomes of 1- vs 2-stent techniques in bifurcation percutaneous coronary interventions (PCI).
Methods: The authors examined the angiographic and procedural characteristics, and outcomes of 1306 bifurcation PCIs (1139 patients) performed at 6 centers between 2014 and 2024 from the PROGRESS-BIFURCATION registry.
Results: Upfront 1-stent PCI (96.
PLoS One
September 2025
Department of Cardiac Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Background: Cardiac ischemia reperfusion (I/R) injury is a serious consequence of reperfusion therapy for myocardial infarction (MI). Peptidylarginine deiminase 4 (PAD4) is a calcium-dependent enzyme that catalyzes the citrullination of proteins. In previous studies, PAD4 inhibition protected distinct organs from I/R injury by preventing the formation of neutrophil extracellular traps (NETs) and attenuating inflammatory responses.
View Article and Find Full Text PDF